Vayssettes-Courchay C, Bouysset F, Laubie M, Verbeuren T J
Division of Angiology, Servier Research Institute, Suresnes, France.
Eur J Pharmacol. 1997 Feb 12;320(2-3):151-9. doi: 10.1016/s0014-2999(96)00897-7.
M7 (5,6-dihydroxy-2-dimethylaminotetralin) produces in anesthetized rats a hypotensive response previously attributed to peripheral dopaminergic mechanisms. We re-examined the effects of this drug on arterial blood pressure, heart rate and sympathetic nerve activity in anesthetized rats and dogs. M7 (1-100 micrograms/kg i.v.) produced in the rats transient dose-dependent pressor effects, with bradycardia and sympatho-inhibition, followed by long-lasting dose-dependent hypotension, bradycardia and sympatho-inhibition. The sympatho-inhibitory and hypotensive effects were comparable in baroreceptor-denervated rats and were reversed by idazoxan (0.1 mg/kg i.v.). The sympatho-inhibitory response induced by M7 (1-100 micrograms/kg) was prevented by treatment with the specific alpha 2-adrenoceptor antagonist, 2-methoxy-idazoxan (0.03 mg/kg i.v.). This central effect of M7 was not altered by treatment with the alpha 1-adrenoceptor antagonist, prazosin (0.1 mg/kg i.v.), and was reduced by treatment with the alpha 2-adrenoceptor antagonists, yohimbine (1 mg/kg i.v.) or idazoxan (0.3 mg/kg i.v.), and the dopaminergic antagonists, haloperidol (0.5 mg/kg i.v.) or sulpiride (3 mg/kg i.v.). Bilateral microinjections of M7 (0.3-3 nmol) into the rostroventral medulla in the rat produced dose-dependent hypotension, bradycardia and sympathetic nerve inhibition which were reversed and prevented by bilateral microinjection of 2-methoxy-idazoxan (1 nmol) into the same sites. Microinjections of 2-methoxy-idazoxan into the rostroventral medulla also inhibited the central effects of M7 at 0.03 mg/kg i.v. In anesthetized dogs, M7 administered into the cisterna magna (1-10 micrograms/kg) reduced arterial blood pressure, heart rate and sympathetic nerve activity; these effects were reversed by administration of 2-methoxy-idazoxan (0.03 mg/kg i.v.). In conclusion, M7, a rigid catecholamine, produces a potent central sympatho-inhibitory and hypotensive effect by activation of alpha 2-adrenoceptors.
M7(5,6 - 二羟基 - 2 - 二甲基氨基四氢萘)在麻醉大鼠中会产生一种先前归因于外周多巴胺能机制的降压反应。我们重新研究了该药物对麻醉大鼠和犬的动脉血压、心率及交感神经活动的影响。M7(静脉注射1 - 100微克/千克)在大鼠中产生短暂的剂量依赖性升压效应,伴有心动过缓和交感神经抑制,随后是持久的剂量依赖性低血压、心动过缓和交感神经抑制。在去压力感受器的大鼠中,交感神经抑制和降压效应相当,且可被咪唑克生(静脉注射0.1毫克/千克)逆转。M7(1 - 100微克/千克)诱导的交感神经抑制反应可被特异性α₂ - 肾上腺素能受体拮抗剂2 - 甲氧基 - 咪唑克生(静脉注射0.03毫克/千克)预处理所阻断。M7的这种中枢效应不受α₁ - 肾上腺素能受体拮抗剂哌唑嗪(静脉注射0.1毫克/千克)处理的影响,但可被α₂ - 肾上腺素能受体拮抗剂育亨宾(静脉注射1毫克/千克)或咪唑克生(静脉注射0.3毫克/千克)以及多巴胺能拮抗剂氟哌啶醇(静脉注射0.5毫克/千克)或舒必利(静脉注射3毫克/千克)处理所减弱。向大鼠延髓腹外侧区双侧微量注射M7(0.3 - 3纳摩尔)会产生剂量依赖性低血压、心动过缓和交感神经抑制,而向相同部位双侧微量注射2 - 甲氧基 - 咪唑克生(1纳摩尔)可逆转并阻断这些效应。向延髓腹外侧区微量注射2 - 甲氧基 - 咪唑克生还可抑制静脉注射0.03毫克/千克M7的中枢效应。在麻醉犬中,向小脑延髓池注射M7(1 - 10微克/千克)可降低动脉血压、心率和交感神经活动;这些效应可被注射2 - 甲氧基 - 咪唑克生(静脉注射0.03毫克/千克)逆转。总之,刚性儿茶酚胺M7通过激活α₂ - 肾上腺素能受体产生强大的中枢交感神经抑制和降压作用。